Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The division is expected to grow to over a 100-member strong team by 2022
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
It is the first presbyopia-correcting lens implant for cataract surgery
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
U.S. FDA to decide whether to authorize a booster dose in the coming days
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Subscribe To Our Newsletter & Stay Updated
